Neuraxis (NRXS) Gains from Investment Securities (2022 - 2024)
Neuraxis (NRXS) posted Gains from Investment Securities of -$7493.0 for Q4 2024, down 211.4% sequentially from $6726.0 in Q3 2024, and up 85.93% YoY from -$4030.1 in Q1 2024.
Neuraxis (NRXS) Gains from Investment Securities (2022 - 2024) Analysis & Trends
Neuraxis has reported Gains from Investment Securities for 3 years, with the latest figure at -$7493.0 in Q4 2024.
- Quarterly Gains from Investment Securities rose 85.93% year-over-year to -$7493.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $941.0 (up 100.11% YoY) and the FY2025 annual result came in at $7634.0, up 711.26% from the prior year.
- Gains from Investment Securities declined to -$7493.0 in Q4 2024 per NRXS's latest filing, from $6726.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $90628.0 in Q3 2022 and troughed at -$1.3 million in Q4 2022.
- A 3-year average of -$189185.7 and a median of -$7576.0 in 2024 frame the typical range for Gains from Investment Securities.
- The widest YoY moves for Gains from Investment Securities: up 158.6% in 2023, down 754.16% in 2023.
- Over 3 years, Gains from Investment Securities stood at -$1.3 million in 2022, then jumped by 95.8% to -$53244.0 in 2023, then soared by 85.93% to -$7493.0 in 2024.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$7493.0, $6726.0, and -$7576.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -7,493.00 |
| Dec 31, 2024 | -7,493.00 |
| Sep 30, 2024 | 6,726.00 |
| Sep 30, 2024 | 6,726.00 |
| Jun 30, 2024 | -7,576.00 |
| Jun 30, 2024 | -7,576.00 |
| Mar 31, 2024 | 9,284.00 |
| Mar 31, 2024 | 9,284.00 |
| Dec 31, 2023 | -53,244.00 |
| Dec 31, 2023 | -53,244.00 |
| Sep 30, 2023 | -592,853.00 |
| Sep 30, 2023 | -592,853.00 |
| Jun 30, 2023 | 36,050.00 |
| Jun 30, 2023 | 36,050.00 |
| Mar 31, 2023 | -234,807.00 |
| Mar 31, 2023 | -234,807.00 |
| Dec 31, 2022 | -1.27 Mn |
| Dec 31, 2022 | -1.27 Mn |
| Sep 30, 2022 | 90,628.00 |
| Sep 30, 2022 | 90,628.00 |